Antithrombotic therapy in patients with chronic kidney disease
about
Effective management of venous thromboembolism in the community: non-vitamin K antagonist oral anticoagulantsAntiplatelet Therapy in Hemodialysis Patients Undergoing Percutaneous Coronary InterventionsCardiopulmonary Bypass Without Heparin.D-Dimer elevation and adverse outcomesComparisons between novel oral anticoagulants and vitamin K antagonists in patients with CKD.Patient safety issues in CKD: core curriculum 2015.Thrombotic Role of Blood and Endothelial Cells in Uremia through Phosphatidylserine Exposure and Microparticle ReleaseThe Aryl Hydrocarbon Receptor is a Critical Regulator of Tissue Factor Stability and an Antithrombotic Target in Uremia.Prolonged dual antiplatelet therapy in renal failure: a challenging trade-offAllosterism-based simultaneous, dual anticoagulant and antiplatelet action: allosteric inhibitor targeting the glycoprotein Ibα-binding and heparin-binding site of thrombin.Advances in platelet function testing assessing bleeding complications in patients with coronary artery disease.Anticoagulants in patients with atrial fibrillation and end-stage renal disease.The quest for equilibrium: exploring the thin red line between bleeding and ischaemic risks in the management of acute coronary syndromes in chronic kidney disease patients.Oral P2Y12 Receptor Inhibitors in Hemodialysis Patients Undergoing Percutaneous Coronary Interventions: Current Knowledge and Future Directions.Impact of renal impairment on platelet reactivity and clinical outcomes during chronic dual antiplatelet therapy following coronary stenting.Dual antiplatelet therapy after coronary stenting.Aortic thrombosis in dogs.Oral antiplatelet drugs in patients with chronic kidney disease (CKD): a review.Antithrombotic therapy in end-stage renal disease.Factors associated with abrupt discontinuation of dabigatran therapy in patients with atrial fibrillation in Malaysia.Association of Fibroblast Growth Factor 23 With Atrial Fibrillation in Chronic Kidney Disease, From the Chronic Renal Insufficiency Cohort StudyEfficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial.Impact of cangrelor overdosing on bleeding complications in patients undergoing percutaneous coronary intervention: insights from the CHAMPION trials.Chronic Kidney Disease and Acute Myocardial Infarction: The Story After 1 Year.Effects of statin therapy on platelet reactivity after percutaneous coronary revascularization in patients with acute coronary syndrome.Influence of Kidney Transplant Status on Warfarin Dose, Anticoagulation Control, and Risk of Hemorrhage.Factors Affecting the Quality of Anticoagulation With Vitamin K Antagonists in Venous Thromboembolism Patients.The comparative safety of abciximab versus eptifibatide in patients on dialysis undergoing percutaneous coronary intervention: Insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2).The comparative safety and effectiveness of bivalirudin versus heparin monotherapy in patients on dialysis undergoing percutaneous coronary intervention: Insights from the Blue Cross Blue Shield of Michigan cardiovascular consortium.Anti-thrombotic therapy for atrial fibrillation in patients with chronic kidney disease: Current views.Paroxysmal Atrial Fibrillation in a Patient on Hemodialysis.Impact of renal function on clopidogrel-induced antiplatelet effects in coronary artery disease patients without diabetes mellitusAdvanced chronic kidney disease in patients undergoing transcatheter aortic valve implantation: insights on clinical outcomes and prognostic markers from a large cohort of patients
P2860
Q26746213-86DF64EB-B41E-4E55-B1EC-E565EFCA3373Q26777116-23AE0CBC-3172-410D-9605-24069A38F8A1Q33430000-FEE08F30-64F0-4604-ACBF-C130D209C6D1Q34990303-6EA438DB-EE75-4EF3-84A0-680FFA7E2F26Q35079761-424B718C-95BE-485A-9FC9-BBE7731545BEQ35798287-70AB4F34-2D59-4314-A68D-121DAB234EACQ35844970-754E9BBC-FC72-4E28-8992-15E5327A7695Q36417926-5DA38D11-2686-4BBC-A345-52403365866CQ36437445-55FE7E3E-A083-4C94-AD9A-8FB319D043E6Q36788507-EDF9D2EE-8663-4D92-902B-DAC4D638ACA2Q38027576-8979EADD-9BBE-4ED9-9BCE-F50AE7DCE40CQ38074333-3286CD76-F46C-45FD-B58A-8A044EB4FEC6Q38735704-6AEF8B37-1A86-46AE-A7A0-D6C027AC5249Q38802950-587B0B93-194B-4535-B38E-5C13384CAA1EQ38830472-6E8EE0D2-5F13-49F9-A345-EC80B2AE3CF5Q38866836-AA1702BD-0981-4A2F-B5C2-2A5DEB541793Q38990340-74111DD9-5543-42F8-81C3-058CEC4E5CAFQ39147420-7245B3B2-49DA-4125-9648-F3C672E88329Q39329927-C07C9566-0B1C-4C53-A2A8-6B36CF07EA27Q39567501-34EB843D-32A1-4643-8E2F-9F7EFB11F641Q40643620-5F7A2729-A7B1-48F2-ACA8-8DC2BFACD89FQ41255322-B995C4E4-EC73-48EA-AE37-0776C9ABFDC8Q41708497-58615FDE-2BB1-4FE5-91E5-77824C344F6EQ42746426-24490F1F-C329-466F-BF57-8A6A13A4A130Q47792745-69633C37-6FA6-4D1D-B31E-CAD02428F336Q47920228-A0747526-D8E5-4146-93F3-0D1779B6D8EAQ47992790-754990AB-6D8B-4304-882E-FCEF3F14DC64Q48097465-6C31E2FC-6E64-410E-A417-CCDC21A3A9D4Q48112185-0F75CB71-1B31-49BF-847C-6718416F0B3DQ50075292-C04034F8-2043-4559-A258-9984EB320896Q55508551-A2C13654-D233-4B2F-9FEA-9CB6A080B1EBQ57764335-CD1CF3E7-C170-4325-A3AB-CF7759B7BB25Q57914359-FB2F85A9-7D49-4E7E-9A18-3C2DF8EE5191
P2860
Antithrombotic therapy in patients with chronic kidney disease
description
2012 nî lūn-bûn
@nan
2012 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Antithrombotic therapy in patients with chronic kidney disease
@ast
Antithrombotic therapy in patients with chronic kidney disease
@en
Antithrombotic therapy in patients with chronic kidney disease
@nl
type
label
Antithrombotic therapy in patients with chronic kidney disease
@ast
Antithrombotic therapy in patients with chronic kidney disease
@en
Antithrombotic therapy in patients with chronic kidney disease
@nl
prefLabel
Antithrombotic therapy in patients with chronic kidney disease
@ast
Antithrombotic therapy in patients with chronic kidney disease
@en
Antithrombotic therapy in patients with chronic kidney disease
@nl
P3181
P1433
P1476
Antithrombotic therapy in patients with chronic kidney disease
@en
P2093
D. J. Angiolillo
P304
P3181
P356
10.1161/CIRCULATIONAHA.111.084996
P407
P577
2012-05-29T00:00:00Z